The COVID-19 Patient Confidence Study, a weekly measure of consumer attitudes and behavior, shows that consumer confidence is at the highest levels since the onset of COVID-19.
72% of patients have reported that they are not delaying a doctor visit to discuss a condition. In addition, the majority of patients expect to go to the HCP in the next two months or sooner, while only 37% expected to go in the next two months on April 30.
86% of consumers are comfortable visiting healthcare providers, over twice the confidence of visiting a restaurant or the 36% comfortable attending a public gathering such as a rock concert or sports event.
Physician search has significantly increased across the country from late March. For example, in Nevada, there was an increase of 129%; in Texas, there was an increase of 111%; and in New York an increase of 114%.
The research also shows that telemedicine has played an important role in delivering care. According to the survey, 30% of respondents have participated in telemedicine in the past 3 months and 83% are open to interacting with their care provider virtually.
Infosurv Research is a boutique research agency based in Atlanta, GA.
Velocity Clinical Research appoints new CEO
Ipsen appoints new board director
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Kemp Proteins partners with NeuImmune to advance precision protein production
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Sobi and Innate confirm strategic partnership
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment